clinical trial · NCT07271186
Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease
Diabetic Kidney Disease (DKD)ALN-ANG3EvinacumabALN-ANG3 placeboEvinacumab placebo
brief summary
This study is researching experimental drugs called ALN-ANG3 and evinacumab (called "study drugs"). The study is focused on participants who have diabetic kidney disease. The aim of the study is to see how safe and effective the study drugs are. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times
started
Jan 9, 2026
primary completion
Sep 24, 2027
completion
Apr 7, 2028
last updated
Apr 16, 2026
official title
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of ANGPTL3 Inhibition With Either Small-Interfering RNA Alone or in Combination With an ANGPTL3 Antibody in Participants With Diabetic Kidney Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol